OctoVent and Orient EuroPharma sign licensing agreement over immunotherapeutic candidate
March 28, 2023Medical Communications
OctoVent, subsidiary of Hepalink Pharmaceutical Group, has entered into a license agreement with Taiwan-based Orient EuroPharma (OEP). The two companies …
Novo Nordisk announces results from phase 3 PIONEER PLUS trial
March 28, 2023Research and Development
Novo Nordisk has announced headline results from the phase 3b PIONEER PLUS trial for the safety and efficacy of once-daily …
GSK shares promising clinical trial results for endometrial cancer therapy
March 28, 2023Research and Development
GSK has announced promising results from part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial for Jemperli (dostarlimab) alongside standard-of-care chemotherapy …
PMGroup announces launch of new recruitment platform PharmaRole
March 28, 2023Business Services
PMGroup Worldwide Ltd (PMGroup) has announced the launch of its new recruitment platform, PharmaRole.com, designed to make it as simple …
Particle Works partners with Earli Inc. to develop DNA-LNPs for early-stage cancer treatment
March 27, 2023Business Services
Particle Works, a leading provider of innovative microfluidic nanoparticle synthesis platforms, is supporting Earli Inc. in its mission to detect, …
Revolo Biotherapeutics Announces Completion of Phase 2a Trial of ‘1104 in Allergic Disease
March 27, 2023Business Services
NEW ORLEANS, LA and CAMBRIDGE, England, March 27, 2023 – Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing …
Statement Following Jounce Therapeutics Announcement of a Definitive Merger Agreement with Concentra Biosciences and Withdrawal of their Recommendation for the Business Combination with Redx
March 27, 2023Business Services
Alderley Park, UK 27 March 2023 Redx Pharma (“Redx”, AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing …
MHRA Grants Conditional Marketing Authorisation in Great Britain to CSL’s HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Haemophilia B
March 27, 2023Business Services
This medicine is subject to additional monitoring.This will allow quick identification of new safety information.
Avacta to present pre-clinical data on AVA3996 at the American Association for Cancer Research Annual Meeting
March 27, 2023Business Services
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces it will …
Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
March 27, 2023Business Services
Leiden, The Netherlands, March 24, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the …
Novartis announces positive results from phase 3 trial of Kisqali for early breast cancer
March 27, 2023Research and Development
Novartis has announced positive results from its phase 3 NATALEE trial assessing Kisqali (ribociclib) along with endocrine therapy (ET) in …
Abberior installs new STED microscope at MBC BioLabs
March 27, 2023Medical Communications
Abberior has announced that it has placed a super-resolution STED microscope at MBC BioLabs, which is the leading San Francisco …
FDA releases draft of accelerated approval guidance for oncology therapeutics
March 27, 2023Medical Communications
The FDA has released a draft of new guidance for accelerated approval for oncology therapeutics, highlighting the need for stricter …
University of Leipzig and SiSaf partner over Bio-Courier targeted miRNA
March 27, 2023Medical Communications
SiSaf, an RNA delivery and therapeutics company, has announced a collaboration with the University of Leipzig to develop Bio-Courier targeted …
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
March 24, 2023Business Services
NEW YORK and BERLIN, March 24, 2023 (GLOBE NEWSWIRE) — atai Life Sciences&
Announces publication of XF-73 nasal gel Phase 2 data in leading US journal Infection Control & Hospital Epidemiology Demonstrates significant reduction of nasal S. aureus in preoperative cardiac surgery patients
March 24, 2023Business Services
Brighton, United Kingdom – 24 March 2023 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the …
NICE recommends PTC Therapeutics’ gene therapy for NHS use
March 24, 2023Medical Communications
NICE has recommended PTC Therapeutics’ gene therapy to the NHS for the treatment of ultra-rare disease aromatic L-amino acid decarboxylase …
Creative Medical Technology files FDA ODD application for Brittle Type 1 diabetes
March 24, 2023Medical Communications
US-based biotech company Creative Medical Technology has announced that it has filed for the FDA’s Orphan Drug Designation (ODD) for …
European Commission delays release of major changes to pharma legislation
March 24, 2023Medical Communications
The European Commission (EC) has again delayed the release of its new proposal for changes to Europe’s pharma legislation. The …
NeuroRPM announces FDA clearance for AI monitoring app for Parkinson’s disease on Apple Watch
March 24, 2023Medical Communications
NeuroRPM has announced that it has received clearance from the FDA for its NeuroRPM device which uses AI and existing …
Latest content
FibroFind appoints Lee Borthwick as CEO
